Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden

Scandinavian Journal of Infectious Diseases

Volumn 43, Issue 4, 2011, Pages 304-312

  Thuresson, Per Olof ^a   Heeg, Bart ^a   Lescrauwaet, Benedicte ^b   Sennfält, Karin ^b   Alaeus, Annette ^b   Neubauer, Aljoscha ^b  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

cost utility; Health economics; Markov model; protease inhibitor

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIARRHEA; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIDDEN MARKOV MODEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SWEDEN; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HIV-1; HUMANS; LOPINAVIR; MODELS, STATISTICAL; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES; QUALITY-ADJUSTED LIFE YEARS; RITONAVIR; SWEDEN;

EID: 79952687014     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2010.545835     Document Type: Article

References (29)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9.
2. d 'A rminio MA, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the fi rst highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. ICONA Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000;14:499-507. (Pubitemid 30209692)
3. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week effi cacy and safety results of the CASTLE study. J Acquir Immune Defi c Syndr 2010;53: 323-32.
4. Josephson F, Albert J, Flamholc L, Gisslen M, Karlstrom O, Moberg L, et al. Treatment of HIV infection: Swedish recommendations Scand J Infect Dis 2009;41:788-807.
5. Apotekeket AB. Apotekens totala för s äl jning av humanl ä kemedel 2007 Total sales of human drugs 2007]. Sweden: Apoteket AB; 2008. Available at: http://www.apotekens service.se/Global/Exter-na%20webben/ statistik/L% c3%a4kemedel%202009/RED%20Humanlm%201-7-st% c3%a4llig%20ATC%2007%2008%2009%20AUP% 20DDD%20m%20kompl%20Apotekens%20Service. pdf (accessed on 2009 September 4).
6. Ortiz R, DeJesus E, Khanlou H, Voronin E, van Lunzen J, ndrade-Villanueva J, et al. Effi cacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatmentnaive HIV-1-infected patients at week 48. AIDS 2008;22: 1389-97.
7. Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, et al. Effi cacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007;370:49-58. (Pubitemid 47023100)
8. Statistiska Centralbyran (Statistics Sweden). Statistik från SCB Life-tables]. Stockholm: Statistics Sweden; 2008.
9. D 'A gostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-81. (Pubitemid 30090804)
10. Dental and Pharmaceutical Benefi ts Agency. Guidelines for economic evaluations from the Pharmaceutical Benefi ts Board (LFNAR 2003:2); Sweden: LFNAR; 2003. Available at: http://www.tlv.se/Upload/English/ENG-lfnar-2003-2.pdf (accessed 19 October 2009).
11. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-8. (Pubitemid 43884298)
12. Gazzard G. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy. HIV Med 2008;9:563-608.
13. Lundgren J, Reiss P, Worm S, Weber R, El-Sadr W, De Wit S. Risk of myocardial infarction with exposure to specifi c ARV from the PI, NNRTI, and NRTI drug classes: the D:A:D Study. abstract]. 16th Conference on REtroviruses and Opportunistic Infections; 2009 February 8-11; Montreal. Abstract nr 44.
14. Anderson KM, Odell PM, Wilson P, Kannel WB. Cardiovascular disease risk profi les. Am Heart J 1990;121:293-8.
15. Tramarin A, Parise N, Campostrini S, Yin DD, Postma MJ, Lyu R, et al. Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy. Qual Life Res 2004;13:243-50. (Pubitemid 38315237)
16. Bishop M, Fody E, Schoeff L. Clinical chemistry: principles, procedures, correlations. Fifth ed. Lippincott Williams & Wilkins, Philadelphia, PA, US, 2008.
17. Statistiska Centralbyrån (Statistics Sweden). Average salary data for September 2008. Stockholm: Statistics Sweden; 2010. Available at: http://www.ssd.scb.se/databaser/makro/MainTable. asp?yp- bergman&xu- scb&omradekod- AM&omra detext- Arbetsmarknad&lang- 1&langdb- 1 (accessed on 2009 September 4).
18. Hubben GA, Bishai D, Pechlivanoglou P, Cattelan AM, Grisetti R, Facchin C, et al. The societal burden of HIV/AIDS in northern Italy: an analysis of costs and quality of life. AIDS Care 2008;20:449-55. (Pubitemid 351652493)
19. Statistiska Centralbyrån (Statistics Sweden). Arbetskraftsunders ökningar 2008. Stockholm: Statistics Sweden; 2010. Available at: http://www.pubkat.scb.se/Pages/Product-23262. aspx (accessed on 2009 September 4).
20. Mukherjee J, Wu Y, Odeshoo L, Kelleher T, Iloeje U, Cross A, Giordano M. Atazanavir maintained patient utility and improved quality of life comparing favorably to LPV/RTV: 24-week data from BMS 043. Oral presentation at the 9 th European AIDS Conference, Warsaw, Poland, 25-29 October 2003.
21. Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defi c Syndr 2003;34:379-86. (Pubitemid 37444465)
22. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defi c Syndr 2006;43: 27-34. (Pubitemid 44306484)
23. Simpson KN, Rajagopalan R, Dietz B. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir- ritonavir regimens in the CASTLE study. Adv Ther 2009;2:185-93.
24. Law MG, Friis-Moller N, El-Sadr WM, Weber R, Reiss P, d 'Arminio MA, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006;7:218-30.
25. Zethraeus N, Molin T, Henriksson P, Jön sson B. Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med 1999;246:151-9. (Pubitemid 29378920)
26. Berg J, Fidan D, Lindgren P. Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials. Curr Med Res Opin 2008;24:2089-101.
27. Miksad RA, Schnipper L, Goldstein M. Does a statistically signifi cant survival benefi t of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical signifi -cance and value? J Clin Oncol 2007;25:4506-7. (Pubitemid 350013866)
28. Schmier JK, Palmer CS, Flood EM, Gourlay G. Utility assessments of opioid treatment for chronic pain. Pain Med 2002;3:218-30. (Pubitemid 35314810)
29. Heeg BM, Peters R, Botteman M, van Hout B. Long-term clopidogrel therapy in PCI patients. Pharmacoeconomics 2007;25:769-82.